A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers

This study has been completed.
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: October 11, 2006
Last updated: May 31, 2012
Last verified: February 2011

GSK189254 is a highly potent histamine 3 (H3) receptor antagonist which has demonstrated efficacy in the reduction of mechanical hyperalgesia and allodynia in the chronic constriction injury pre-clinical model of neuropathic pain (NP). The mechanism of action of GSK 189254 in the pain model is hypothesised to be via enhanced release of monoamines in the central nervous system (CNS). A similar mechanism of action has also been shown for duloxetine. In this phase I study, the safety and efficacy of GSK189254 will be investigated in the electrical hyperalgesia (EH) model in healthy volunteers to build confidence that the preclinical efficacy demonstrated by this compound will translate into patients.

This study will be conducted as a double-blind, double-dummy, placebo-controlled, incomplete block, two period crossover study. Up to 40 healthy male or female volunteers, aged 18-45 years old, will be randomised into the study in order to achieve 32 evaluable subjects. Subjects will undergo two 3-week treatment periods and will be randomised to receive placebo and either GSK189254 (up to 100µg once daily) or duloxetine (up to 60mg daily). There will be a one week washout between treatment periods. The effects of repeated oral dosing of GSK189254 and duloxetine on secondary hyperalgesia in the EH model will be determined. Subject: GSK189254, Neuropathic pain (NP), H3 antagonist, duloxetine, Electrical hyperalgesia, Phase I, Healthy volunteers, Double blind, Safety, tolerability.

Condition Intervention Phase
Healthy Subjects
Drug: Duloxetine
Drug: GSK189254
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-blind, Double-dummy, Placebo-controlled, Incomplete Block, Two Period Crossover Study of the Histamine H3 Antagonist GSK189254 and Duloxetine in the Electrical Hyperalgesia Model of Central Sensitisation in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Area of pin-prick hyperalgesia Area of touch-evoked allodynia [ Time Frame: The mortality of above measurements at 7 months, functional status for each subject at 8-10 weeks. ]

Secondary Outcome Measures:
  • Ongoing pain intensity rating Area and intensity of flare Mood and alertness [ Time Frame: The mortality for above measurements at 7 months, functional status for each subject 8-10 weeks. ]

Enrollment: 40
Study Start Date: October 2006
Intervention Details:
    Drug: Duloxetine Drug: GSK189254
    Other Name: Duloxetine

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • He/she is a healthy subject.
  • Women of child bearing potential must have a negative pregnancy test at screening and have undergone, or confirm regular use of one of the following:

Female sterilisation Sterilisation of male partner Practising a clinically accepted method of contraception during the study and for at least one month prior to baseline and one month following completion of the study.

  • Has Caucasian skin colour.
  • Body weight > 50kg and BMI within the range 18.5 to 29.9kg/m2 inclusive.
  • Non smoker.
  • Satisfactory pre-study medical within 28 days prior to the start of the study.
  • No abnormality on clinical examination
  • No abnormality on clinical chemistry or haematology.
  • Negative pre-study urine drug screen and cotinine test.
  • Signed and dated written informed consent prior to admission to the study.
  • The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.
  • Available to complete the study.

Exclusion Criteria:

  • The subject has a positive pre-study urine drug/alcohol screen. A minimum list of drugs that will be screened for include Amphetamines, Barbiturates, Cocaine, Opiates, Cannabinoids, Methadone and Benzodiazepines.
  • The subject has a history of drug or other allergy, that, in the opinion of the responsible physician, contraindicates their participation.
  • A positive pre-study Hepatitis B surface antigen, positive Hepatitis C antibody or positive HIV results.
  • History of clinically significant psychiatric disease, or presence of depressive disorder as defined by HAD depression score >8, or presence of anxiety disorder as defined by HAD anxiety score >8.

History or presence of insomnia or other sleep disorders.

  • A QTcB interval < 430msec (men) or < 450msec (women).
  • The subject has donated >500 mls of blood within 56 days prior to the first dose.
  • Abuse of alcohol defined as an average daily intake of greater than 3 units for men and 2 units for the women.
  • The subject has a history or presence of drug/substance abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.
  • The subject has participated in a study with a new molecular entity during the previous 112 days or any other trial during the previous 84 days.
  • The subject is currently taking regular (or a course of) medication whether prescribed or not. Such a subject may be included if the Investigator considers that this does not compromise safety or study procedures.
  • Has received prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives whichever is the longer, prior to the first dose of study medication
  • The subject has a history of chronic pain before screening.
  • The subject has ingested or used a topical preparation containing aspirin or other non-steroidal anti-inflammatory drugs or paracetamol or other analgesic medication in the 7 days prior to the screening visit.
  • The subject has used any topical steroid in the previous 30 days.
  • The subject has used any topical capsaicin preparations on the forearms in the previous 30 days.
  • The subject suffers from eczema, psoriasis or any other acute or chronic dermatological problem.
  • The subject does not produce an area of allodynia or hyperalgesia to the EH model at screening
  • The subject is unable to tolerate the EH model, including anxiety or atypical response to the model.
  • The subject has any abnormality on diagnostic EEG at screening, or a history or presence of seizures or risk factors for seizure.
  • The subject has any other medical condition that in the opinion of the Investigator would compromise the safety of the subject or the subject's ability to complete the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00387413

United Kingdom
GSK Investigational Site
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00387413     History of Changes
Other Study ID Numbers: H3A106308 
Study First Received: October 11, 2006
Last Updated: May 31, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by GlaxoSmithKline:
Healthy volunteers
Phase I.
Electrical hyperalgesia model

Additional relevant MeSH terms:
Nervous System Diseases
Neurologic Manifestations
Sensation Disorders
Signs and Symptoms
Somatosensory Disorders
Histamine H3 Antagonists
Adrenergic Agents
Adrenergic Uptake Inhibitors
Antidepressive Agents
Central Nervous System Agents
Dopamine Agents
Dopamine Uptake Inhibitors
Histamine Agents
Histamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on February 04, 2016